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INTRODUCTION
Significant progress has recently been made in develop-
ing strategies to mobilize immature hematopoietic pro-
genitor cells from the bone marrow into the peripheral
blood (PB). The rapid, sustained engraftment of these cells
seen after high-dose chemotherapy and radiotherapy has led
to the widespread use of this source of stem cells in patients
who undergo both autologous [1] and allogeneic [2] trans-
plantation. The infusion of most hematopoietic growth fac-
tors leads to an increase in the peripheral blood stem cell
(PBSC) population, but the magnitude of this mobilization
varies and depends on the growth factor used, the dosing
schedule, and the biologic response of the recipient. The
most active single agent identified to date is the myeloid
growth factor granulocyte colony-stimulating factor (G-
CSF) [3]. Administration of this cytokine produces a signifi-
cant increase in the number of circulating PBSCs as meas-
ured by in vitro assays of colony-forming cells (CFCs) and
by the number of phenotypically defined (CD341) pro-
genitor cells.
The use of combinations of growth factors to mobilize
PBSCs is now being evaluated in an effort to increase the
number of circulating progenitor cells in the PB and there-
by reduce the number of leukapheresis products required to
obtain sufficient numbers of PBSCs for transplantation. An
attractive approach to mobilizing greater numbers of these
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ABSTRACT
We investigated the effects of administering a high-affinity interleukin-3 receptor agonist (daniplestim) and granu-
locyte colony-stimulating factor (G-CSF) on the mobilization of primitive hematopoietic progenitor cells into
peripheral blood (PB). Groups of five rhesus monkeys were treated with 100 mg/kg of daniplestim for 5 days fol-
lowed by 10 mg/kg of G-CSF for 5 days (D/G), daniplestim and G-CSF administered concurrently for 10 days
(D1G), or G-CSF alone for 10 days. Phenotypic PB analysis indicated that the number of CD341 cells in the 
G-CSF group had increased to 283106/L by Day 3 and then declined. In contrast, CD341 cell counts of up to
683106/L were maintained until Day 10 in both the D/G and D1G groups. On Day 5, the total number of colony-
forming cells in the PB had increased 15-fold in the D1G group and eightfold in both the D/G group and the 
G-CSF groups. By Day 7, the numbers of colony-forming units granulocyte/macrophage were comparable in all
three groups, and 45-fold increases in the numbers of burst-forming units-erythroid and 12-fold increases in the
numbers of multipotent colony-forming units were seen in both the D1G and the D/G groups. The frequency of
circulating primitive progenitor cells in long-term stromal cultures was highest with D1G and lowest with G-CSF
alone. These results indicate that the combination of daniplestim and G-CSF produces higher and more sustained
levels of circulating stem cells than does G-CSF alone. D1G may offer advantages over D/G because it generates
more long- and short-term clonogenic cells.
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cells involves priming the bone marrow with an early-acting
cytokine to increase the number of progenitor cells, fol-
lowed by treatment with a later-acting factor that has
significant mobilizing activity.
The synergistic effect of interleukin-3 (IL-3) and granu-
locyte-macrophage colony-stimulating factor (GM-CSF) on
colony formation in vitro [4,5] suggests that the administra-
tion of these factors in combination may substantially
increase the mobilization of PBSCs. Studies in both rhesus
monkeys and humans have examined the sequential admin-
istration of IL-3 followed by either G-CSF [6–8] or GM-
CSF [9–14]. These studies have shown that these combina-
tions of cytokines successfully mobilize PBSCs, but side
effects, including fevers, headache, arthralgias, and myalgias
are associated with the administration of IL-3 [6,7,9,10]. A
similar side-effect profile has been observed in patients
treated with IL-3 for bone marrow failure [15]. In addition,
inflammatory reactions that are both dose-dependent and
related to the duration of treatment have been described in
nonhuman primates [16].
To enhance the efficacy of IL-3, a family of IL-3 recep-
tor agonists has been engineered to increase the hemato-
poietic activity of this molecule without substantially
increasing its inflammatory activity. Daniplestim (SC-55494,
Searle Research and Development, St. Louis, MO), a novel
species-specific IL-3 receptor agonist, has been shown to be
10-fold more active in proliferation assays and more than
20-fold more active in CFC assays than native IL-3 [17].
This advantage is offset by a twofold increase in the release
of inflammatory response molecules such as histamine and
leukotrienes, so that the overall potential therapeutic index
of daniplestim over IL-3 is estimated to be five- to 10-fold
[17]. When daniplestim was administered to nonhuman pri-
mates with radiation-induced myelosuppression, a more
rapid recovery of both platelets and neutrophils was
observed, indicating the multilineage activity of this IL-3
receptor agonist [18]. Combined therapy with daniplestim
and G-CSF after radiation exposure reduces the magnitude
and duration of neutropenia and thrombocytopenia to a
greater degree than does daniplestim alone or G-CSF alone
[19]. In the present study we have evaluated the potential of
daniplestim administered concurrently or sequentially with
G-CSF to mobilize PBSCs in nonhuman primates.
PATIENTS AND METHODS
Animals
Rhesus monkeys (Macaca mulatta) that weighed 6–8 kg
were maintained at the Yerkes Regional Primate Center in
Atlanta, GA. All experimental procedures were approved by
the Institutional Animal Care and Use Committee of Emory
University.
Growth factor administration
Three groups of five animals were injected subcuta-
neously with 100 mg/kg daniplestim for 5 days followed by
10 mg/kg of G-CSF for 5 days (D/G), daniplestim and G-
CSF concurrently for 10 days (D1G), or G-CSF alone for
10 days. Injections were rotated among different sites on the
abdomen and the flanks, and the injection sites were moni-
tored daily for signs of inflammation.
PB samples
PB was obtained during ketamine hydrochloride anes-
thesia before the administration of the growth factors (Day
0) and on Days 3, 5, 7, 10, 12, and 14 of treatment. On each
of these days, 4 mL of PB was collected; 1 mL was immedi-
ately transferred to a tube containing ethylenediaminetetra-
acetic acid (EDTA). The remaining 3 mL was mixed with 1
mL of Hanks’ balanced salt solution containing 3% fetal
calf serum and 150 U heparin, and was used to prepare
mononuclear cells.
Complete blood counts
Using a Coulter counter (TM, Coulter Electronics,
Miami, FL) calibrated for rhesus peripheral blood cells, the
total leukocyte count, serum hemoglobin level, hematocrit,
and platelet count were determined. Manual differential
counts were performed and the absolute number of neu-
trophils, lymphocytes, monocytes, basophils, and eosinophils
per unit volume was obtained by counting 100 peripheral
blood leukocytes.
CD341 cell determination
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by density centrifugation using ficoll-hypaque
(Histopaque-1077, Sigma Chemical, St. Louis, MO). The
PBMCs were washed twice in a phosphate-buffered saline
solution containing 1% bovine serum albumin and were
incubated for 20 minutes at 48C with a biotinylated anti-
body to CD34 (12.8, Cell Pro, Bothell, WA) [20]. The cells
were washed, resuspended, and incubated with both a 
second-stage streptavidin-phycoeyrthrin and an antibody
directed against CD45RA-FITC (BDIS, Sunnyvale, CA).
The cells were washed and resuspended in modified Hanks’
balanced salt solution containing 1 mg/mL propidium
iodide. The number of CD341, CD45RA1 mononuclear
cells was determined by flow cytometry. Nonspecific bind-
ing was evaluated by using the appropriate second-stage
and isotype controls. For each sample 50,000 cells were
analyzed, providing a sensitivity of detection of 0.1% of the
total number of PBMCs. The total number of CD341,
CD45RA1 cells per unit volume of PB was calculated by
multiplying the percentage of the PBMCs that expressed
CD45RA and CD34 by the number of mononuclear cells
per unit volume of blood.
Methylcellulose colony assays
Total PBMCs were prepared as described above, then
cultured in Iscoves’s Methylcellulose Ready-Mix serum sup-
plemented with erythropoietin (3 U/mL; StemCell Tech-
nologies, Vancouver, BC), 50 mL of phytohemagglutinin-
stimulated conditioned medium, and 1% fetal bovine serum
[21]. Tissue culture plates containing 0.3–1.03105 input cells
were incubated in triplicate at 378C and 5% CO2 for 14 days.
The numbers of colony-forming unit granulocyte/macro-
phage (CFU-GM), colony-forming unit-erythroid (CFU-E),
burst-forming unit-erythroid (BFU-E), and multipotent
colony-forming unit (CFU-GEMM) colonies (.50 cells)
were scored by using an inverted microscope. The number
of colonies per unit volume of PB was determined by multi-
plying the number of colonies produced per input cell by the
total number of mononuclear cells per unit volume of blood.
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Long-term stromal cell cultures and limit dilution assays
The AC-6 stromal cell line was cultured in 96-well plates
as previously described [22]. The PBMCs were suspended in
RPMI/IMDM media with 10% fetal calf serum and stem cell
factor at 0.5 ng/mL. Serial dilutions of these cells were added
to confluent AC-6–containing wells (200–60,000 cells per
well). These cultures were fed each week with 100 mL of
RPMI/IMDM media. Those wells in which there were 
cobblestone-area-forming cells (.100 viable cells) after 28
days of culture were scored as positive. The number of cells
that gave rise to 37% negative wells was determined [23].
This value indicates the number of early clonogenic precur-
sors that have the potential to sustain colony formation for
up to 28 days on this stromal feeder system.
RESULTS
Monitoring of adverse effects associated with cytokine
administration
All animals were examined at least once daily for any
adverse effects from the treatment. The injection sites did
not show any signs of inflammation or any abrasions charac-
teristic of a pruritic reaction. The food intake, weight, and
activity levels of all animals were stable throughout the
treatment period. PB samples were obtained by using keta-
mine anesthesia, which made it possible to assess the periph-
eral lymph nodes and spleen size during the treatment peri-
od. No adenopathy or splenomegaly was detected in any of
the animals. In summary, all 15 animals in the three treat-
ment groups tolerated the daily injections of these cytokines
without showing any adverse effects.
Effects of cytokine administration on PB counts
After 5 days of treatment, the total white blood cell,
neutrophil, and mononuclear cell counts in the D/G group
remained unchanged (Fig. 1). In contrast, an eightfold
increase in the number of circulating neutrophils and a 1.8-
fold increase in the number of mononuclear cells were
observed in the D1G and the G-CSF groups. By Day 10
the total white blood cell count had peaked in all three
treatment groups, with levels ranging from 34.53109/L (G-
CSF) to 60.13109/L (D/G), a four- to sixfold increase over
the pretreatment levels (Fig. 1A). In all three groups the
majority of these circulating cells were neutrophils (Fig. 1B);
however, up to a twofold increase in the total number of cir-
culating mononuclear cells was observed (Fig. 1C). Both the
total white blood cell count and the neutrophil count
returned rapidly to baseline levels after the cytokine was
stopped. A similar decline in the number of mononuclear
cells was observed in the G-CSF group and the D/G group;
however, numbers of mononuclear cells that were 1.8-fold
greater than the pretreatment levels were maintained in the
D1G group for up to 4 days after the cessation of cytokine
treatment. No clinically significant differences in the hemo-
globin level, hematocrit, or platelet count were observed
among the three treatment groups (data not shown).
Mobilization of CD341 progenitor cells into the PB
The number of phenotypically defined hematopoietic
progenitor cells in the mononuclear fraction of the PB was
determined during the 10-day treatment period. When
Figure 1. Effects of daniplestim and granulocyte colony-stimulat-
ing factor (G-CSF) on peripheral blood cells
Cohorts of five rhesus monkeys were treated with either daniplestim for 5 days
and then G-CSF for 5 days (j), daniplestim and G-CSF concurrently for 10
days (d), or G-GSF alone for 10 days (m). Peripheral blood samples were
obtained and the number of total (A) nucleated cells, (B) neutrophils, and
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mononuclear cell preparations were examined, it was found
that almost all CD341 cells also expressed the CD45RA
antigen. Before treatment the mean level of CD341 pro-
genitor cells in the PB was 133106/L (Fig. 2). After 5 days
of D1G administration, the number of circulating CD341
progenitor cells had increased to 543106/L. The number of
CD341 cells in the D/G group had increased to only
203106/L by Day 5 (the last day of daniplestim treatment);
however, in the G-CSF phase of the sequential-cytokine
regimen, the cell count increased to 633106/L within 2 days
and this value was maintained through day 10. The maximal
increase in the CD341 cell count in the group that was
given G-CSF only was 433106/L by Day 3. The count
returned to the baseline value by Day 5 and did not increase
again during the treatment period. These results indicate
that the early maximal increase in phenotypically defined
progenitor cells occurs after the concurrent administration
of daniplestim and G-CSF.
Mobilization of the total population of colony-forming
hematopoietic progenitor cells
To determine the level of committed hematopoietic pro-
genitors in the PB following cytokine treatment, we assayed
PBMCs for their ability to differentiate into myeloid (CFU-
GM), erythroid (CFU-E and BFU-E), and mixed colonies
(CFU-GEMM). The total number of colonies generated
per 105 input cells was determined in each treatment group.
The pretreatment numbers of total colonies per 105 input
cells ranged from 3.8 to 6.4 (Fig. 3A). After 5 days of treat-
ment, the number of colonies had increased ninefold in the
D1G group (55 colonies), sevenfold in the D/G group (29
colonies), and 4.7-fold (30 colonies) in the G-CSF group.
By Day 11 the number of colonies had peaked in all three
treatment groups. A peak activity of 73 colonies per 105
input cells was seen in the D1G group; the corresponding
values in the D/G and G-CSF groups were 61 and 41 per
105 input cells, respectively. The colony-forming activity of
the mononuclear fraction of the PB was increased in all
treatment groups, but the greatest increases were observed
in the concurrent-treatment group. In both groups given
daniplestim, the increase in activity on a per-cell basis was
greater than that in the group given only G-CSF.
To determine the colony-forming activity of circulating
hematopoietic progenitor cells, we calculated the total num-
ber of CFCs per unit volume of PB. The number of CFCs
before treatment was between 201 and 363 3103/L in all
three groups (Fig. 3B). By Day 5 there was an eightfold
increase in the number of CFCs in the G-CSF and D/G
groups. In contrast, there was a 15-fold increase in the
D1G group. By Day 10 the values were 72553103/L in the
D/G group and 58223103/L in the D1G group, but only
24583103/L in the G-CSF group. The levels of circulating
CFCs were higher in the D1G group than in the G-CSF
group throughout the 10 days of treatment. The levels were
lower in the D/G group than in the D1G and G-CSF
groups during the 5 days of daniplestim treatment. When
G-CSF was given in the D/G group, however, the levels
increased rapidly and continued to increase throughout the
period of G-CSF treatment. This finding is consistent with
an increase in the number of CFCs in the bone marrow,
which is induced by daniplestim and followed by the release
of these cells into the periphery by G-CSF. By Day 10 the
number of circulating CFCs in the D/G group was 36-fold
higher than the pretreatment level, but only eightfold high-
er in the G-CSF group. In all three treatment groups, there
was a decrease in the concentration of CFCs when the
growth factor was discontinued. These findings indicate
that both the progenitor activity per mononuclear cell and
the progenitor activity per unit volume of PB are highest in
the D1G group.
Mobilization of lineage-specific progenitor cells
When the effects of cytokine mobilization on the number
of lineage-specific progenitor cells were evaluated, clear dif-
ferences were observed after 7 days of treatment (Fig. 4). The
number of CFU-GM was similar in each group, ranging from
a mean of 130 colonies per 106 input cells to 281 colonies per
106 cells. The number of BFU-E colonies was markedly dif-
ferent in the treatment groups, with a mean of 0.8 colonies
per 106 input mononuclear cells in the G-CSF group and
means of 36 and 43 colonies per 106 input cells in the D/G
and D1G groups, respectively. This difference in the number
of erythroid precursors was more pronounced when the
CFU-E were examined. A mean of 20 CFU-E per 106 input
cells was seen in both the D/G group and the D1G group. In
contrast, no CFU-E were detected in the G-CSF group.
Mixed myeloid and erythroid colonies (CFU-GEMM) are
believed to arise from more primitive bipotential progenitor
cells. Both the D/G group and the D1G group had a mean
of 16 colonies per 106 input cells, but the G-CSF group had a
mean of only 1.4 colonies per 106 input cells. These results
indicate that both D1G and D/G produce higher levels of
Figure 2. Effects of daniplestim and G-CSF on CD341 cell counts in
the peripheral blood
The number of CD341 cells circulating in the peripheral blood after treat-
ment with daniplestim followed by G-CSF (j), daniplestim plus G-CSF (d),
and G-CSF alone (m) was determined. The mean and SEM for groups of five
animals are shown.
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circulating erythroid progenitor cells and early mixed-lineage
progenitor cells than does G-CSF alone.
Detection of early hematopoietic progenitor cells
To determine the presence of primitive hematopoietic
cells with the ability to generate colonies in long-term cul-
ture, we performed a limit dilution assay. The number of
clonogenic precursors was determined by using Poisson
analysis [23,24]. The number of these progenitor cells was
highest in the D1G group, in which there was a fourfold
increase in the number of circulating progenitor cells by
Day 7. In the D/G group there was a twofold increase and
in the G-CSF group a 1.5-fold increase within the same
time period (Fig. 5). The levels of progenitor cells peaked
by Day 7 in all three treatment groups and then declined to
levels below baseline by Day 10. These results indicate that
an increase in the levels of circulating early progenitor cells
occurs earlier and is less sustained than the mobilization of
the more differentiated methylcellulose colony-forming
progenitor cells.
DISCUSSION
Early studies of IL-3 found that this pleiotropic species-
specific growth factor [25] interacts with early progenitor
cells [26] and produces a marked increase in the activity of
later-acting lineage-specific cytokines. In vitro studies of
murine progenitor cells indicate that the combination of
homologous IL-3 and G-CSF increases the formation of
multipotential blast colonies [4]. When human bone mar-
row cells were evaluated in culture, a synergistic effect on
colony growth was observed when IL-3 was combined with
either G-CSF or GM-CSF [5]. The administration of IL-3
in nonhuman primates was found to have a modest effect on
hematopoiesis; however, pretreatment with IL-3 greatly
potentiated the hematopoietic response to GM-CSF
[11,12]. When IL-3 was administered to patients with bone
marrow failure [15], an increase in the numbers of reticulo-
cytes, leukocytes, and platelets was observed, confirming the
multilineage activity of this hematopoietic growth factor.
Analysis of human hematopoietic progenitor cells after
the administration of IL-3 showed an increase in DNA syn-
thesis [27]. This proliferation of progenitor cells was accom-
panied by an increase in bone marrow cellularity and an
increase in the myeloid-to-erythroid cell ratio. These obser-
vations suggested that IL-3 could be used to expand early
hematopoietic progenitor cells within the bone marrow.
The subsequent addition of GM-CSF or G-CSF would be
expected to mobilize these expanded bone marrow–derived
progenitor cells into the PB. When this hypothesis was test-
ed in rhesus monkeys, a 12-fold increase in the number of
circulating CFU-GM was observed with IL-3 alone and a
63-fold increase with IL-3 followed by GM-CSF [13]. A
subsequent phase I study in humans found that the sequen-
tial administration of IL-3 and GM-CSF was more effective
in increasing the number of circulating CFU-GM than was
IL-3 alone [9]. In another study, the mobilization of pro-
genitor cells after chemotherapy, IL-3, and GM-CSF was
greater than that with chemotherapy and IL-3 alone [28].
Successful mobilization in patients treated with IL-3 fol-
lowed by G-CSF with or without prior chemotherapy has
resulted in levels of circulating progenitor cells sufficient to
enable autografting [6,7]. When autologous PBSCs mobi-
lized with IL-3 followed by GM-CSF were infused into
patients who had been treated with high-dose chemo-
therapy, hematopoietic engraftment was observed [10,14].
In a prospective pilot trial to evaluate the relative mobilizing
potential of these cytokine combinations, leukapheresis
products obtained from the sequential administration of IL-
3 followed by GM-CSF resulted in slower engraftment than
did leukapheresis products obtained with IL-3 priming fol-
lowed by G-CSF treatment (22 vs. 13 days) [8]. These find-
Figure 3. Mobilization of hematopoietic progenitor cells into the peripheral blood
(A) The number of colony-forming cells (CFCs) per 105 input mononuclear cells in cohorts of five rhesus monkeys after treatment with daniplestim for 5 days and
then G-CSF for 5 days (j), daniplestim and G-CSF concurrently for 10 days (d), or G-GSF alone for 10 days (m) are shown. (B) The number of CFCs per
unit volume of peripheral blood in each of these treatment groups was determined. The mean and SEM are shown.
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ings underscore the importance of comparing the mobiliz-
ing ability of different cytokines in the same clinical trial.
The goal of our study was to determine whether the
sequential administration of the early-acting IL-3 receptor
agonist daniplestim followed by G-CSF would produce
higher numbers of circulating progenitor cells than would
concurrent administration of these cytokines. For direct
comparison we also treated a group of animals with G-CSF
only. We found that both phenotypically identified and
functionally defined hematopoietic progenitor cells were
mobilized into the PB of nonhuman primates by all three
treatment regimens. The magnitude of the mobilization of
progenitor cells was greater in both the D/G and the D1G
groups than in the G-CSF group. Essentially, all progenitor
cell measurements indicated equal or better results with
concurrent treatment than with sequential treatment.
These findings are consistent with those of a recent study
that evaluated the effects of Flt3/Flt2 ligand on the mobi-
lization of hematopoietic progenitor cells in nonhuman pri-
mates [29]. This ligand slowly mobilized hematopoietic
progenitor cells, with the peak activity occurring after 2
weeks of treatment. The administration of G-CSF during
the last 5 days of a 12-day course of treatment with the
ligand produced levels of circulating progenitor cells that
were 10-fold higher than those observed with the ligand
alone. When a short course of combined treatment with
both agents was given, similar increases in the number of
circulating progenitor cells were observed. Both this study
and our present study clearly show that a period of pre-
treatment with an early-acting multipotent cytokine does
not produce higher levels of circulating progenitor cells
than does a shorter course of concurrent therapy with the
same cytokines.
The early increase in the levels of circulating progenitor
cells seen in the D1G group in our study indicates that this
schedule would likely be more efficacious for collecting
PBSCs and that a shorter treatment period would be
required for mobilization. Further studies to evaluate the
engraftment potential of progenitor cells mobilized by these
treatment schedules appear to be warranted. In addition,
these data suggest that a chimeric molecule consisting of a
bifunctional IL-3 receptor agonist and a G-CSF receptor
agonist may prove useful for mobilizing hematopoietic pro-
genitor cells.
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